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Background: Tendinopathies are often empirically treated with oral/topical nonsteroidal anti-inflammatory
medications and corticosteroid injections despite their unclear effects on tendon regeneration. Recent studies
indicate that tendon progenitors exhibit stem cell-like properties, i.e., differentiation to osteoblasts, adipocytes, and
chondrocytes, in addition to tenocytes. Our present study aims at understanding the effects of triamcinolone
acetonide and diclofenac on tenocytic differentiation of mesenchymal stem cells.
Methods: The murine fibroblast C3H10T1/2 cell line was induced to tenocytic differentiation by growth
differentiation factor-7. Cell proliferation and differentiation with the exposure of different concentrations of
triamcinolone acetonide and diclofenac were measured by WST-1 assay and real-time polymerase chain reaction
analysis, respectively.
Results: Cell proliferation was decreased in a concentration-dependent manner when exposed to triamcinolone
acetonide and diclofenac. In addition to tenocytic differentiation, adipocyte formation was observed, both at gene
expression and microscopic level, when the cells were exposed to triamcinolone acetonide or high concentrations
of diclofenac.
Conclusions: Our results indicate that triamcinolone acetonide and diclofenac might alter mesenchymal stem cell
differentiation in a nonfavorable way regarding tendon regeneration; therefore, these medications should be used
with more caution clinically.
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Tendons are collagenous connective tissues, which con-
nect bones to muscles and are essential for joint move-
ment. The human tendon can withstand considerable
forces during locomotion based on a dense fibrillar net-
work of collagen fibers [1,2]; however, this hypocellular
and hypovascular structure also makes the tendon prone
to overuse injuries, as what often occurs with repetitive
loading in sports and leisure activities [3]. This process is
defined as tendinopathy, which is a common orthopedic
condition characterized by pain during activity, localized* Correspondence: Maritha.Fredrission@ki.se
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distribution, and reproduction in any mediumtenderness upon palpation, swelling of the tendon, and
impaired performance [4]. Tendinopathies around the lar-
ger joints are disabling [5]. The treatments of these condi-
tions are often empirically initiated with oral/topical
nonsteroidal anti-inflammatory medications (NSAIDs)
and/or corticosteroid injections [6]. The aim is to reduce
symptoms and promote mobilization. However, the bio-
logical/pharmacological basis of these methods, especially
their effects on tendon regeneration, is largely uncertain
[7-9].
The repair activity following tendon injury is associated
with fibroblast-like cells from the epitenon and endotenon,
termed as tenoblasts. They are immature, proliferative
cells and are considered as precursors of terminally differ-
entiated tenocytes, which are responsible for matrix
synthesis [10]. Recent studies indicate that these ‘niched’tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Sequences of used oligonucleotide primers
Primer sequence
Targets Forward primer Reverse primer
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to differentiate into cells of a variety of mesenchymal tis-
sues, such as the bone, fat, and cartilage, in addition to the
tendon [12,13]. Interestingly, tendinopathy is histologically
characterized with a marked reduction in the amount of
healthy tenocytes and the accumulation of ‘non-tendon
cells’, including myofibroblasts, adipocytes, chondrocytes,
and osteoblasts [14]. Therefore, tendinopathy might result
in impairment of tenocytic differentiation of the stem cells
which are directed towards other mesenchymal lineages
under pathological condition.
Our present in vitro study aimed to evaluate the influence
of NSAIDs and corticosteroid on tenocytic differentiation
of mesenchymal stem cells (MSC). We used the well-
established murine mesenchymal cell model C3H10T1/2
where cells were induced to tenocytic differentiation
through the treatment with growth differentiation factor-7
(GDF-7), which has been reported to induce tenogenic
maturation in tendon-derived cells [15-18]. The effects of
diclofenac (DF) and triamcinolone acetonide (TA) on cell
proliferation and lineage differentiation were evaluated.
Methods
Cell culture
Murine mesenchymal stem cells, C3H10TY1/2 (LGC
Standards) were routinely cultured in Dulbecco's BME
medium (Invitrogen, Life Technologies, Carlsbad, CA,
USA) supplemented with 10% heat-inactivated fetal bovine
serum (Saveen Werner, Limhamn, Sweden), 1% gentami-
cin (Invitrogen) and 1% L-glutamate (Invitrogen) in an
incubator with 95% O2 and 5% CO2.
Cell proliferation assay
In 96-well plates, 700 cells per well were seeded and
allowed to adhere overnight. The next day (day 0), cells
were exposed to DF (0.1–100 μM; Sigma) or TA (1 nM–
1 μM (Sigma-Aldrich Corporation, St. Louis, MO, USA).
The medium was changed every third day. Cell growth was
analyzed on days 0, 1, 3, and 5 with WST-1 kit (Roche,
Besel, Switzerland), where a tetrazolium salt is cleaved to
formazan by cellular enzymes, i.e., mitochondrial succinate
dehydrogenase. Increase of enzyme activity leads to in-
creased formazan dye formation, which correlates to the
number of metabolically active cells in culture. The formed
dye was quantified with SpectraMax 250 microplate reader
(Molecular Devices, LLC, Sunnyvale, CA, USA) against a
background control.
Differentiation and treatment groups
Cells plated in six-well plates were differentiated towards
tenocytic lineage using GDF-7 (R&D Systems, Minneap-
olis, MN, USA) at a final concentration of 50 ng/ml.
Ascorbic acid was also added to a final concentration of
50 μg/ml to support proper collagen synthesis. From thestart of differentiation and up to 9 days of treatment, differ-
entiating cells were exposed to DF (0.1–100 μM) or TA
(1 nM–1 μM) and then analyzed for expression of tenocyte,
osteoblast, and adipocyte markers as described below.
Quantitative real-time polymerase chain reaction assay
Cells were grown in six-well culture plastic plates for 0–
9 days and then lysed using Trizol reagent (Invitrogen) and
RNA, prepared as described by manufacturer. Isolated
RNA (1 μg) was subjected to DNase treatment (Invitrogen)
and thereafter reverse-transcribed with Super Script II
reverse transcriptase to cDNA using random primers
(Invitrogen). cDNA was subjected to real-time polymerase
chain reaction (RT-PCR) with SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA, USA) in an ABI
PRISM 7500 apparatus (Applied Biosystems). Reaction con-
ditions were 1 cycle at 95°C for 20 s followed by 40 cycles
at 90°C for 3 s and at 60°C for 30 s. Primer sequences are
described in Table 1.
Statistical methods and data management
Multiple comparisons of continuous data were performed
by analysis of variance (ANOVA). In the case of a statisti-
cally significant result in the ANOVA, statistical compari-
sons in order to test differences between groups, post hoc
comparisons, were made using Dunnett's post hoc test
when comparing a control group with the other groups,
and the post hoc procedure proposed by Bonferroni was
used to control for multiplicity when comparing arbitrary
groups. All analyses were carried out using the SPSS
system.
Results
Effect of TA and DF on proliferation of MSC
Exposure of MSC to TA had a negative effect on prolif-
eration, as measured with WST-1 cell proliferation
assay (Figure 1). At day 3 of exposure, a negative effect
on proliferation was noticed with the tested concentra-
tions of TA. At day 5, all tested concentrations clearly
influenced proliferation in a concentration-dependent
manner. The NSAID, diclofenac, also decreased cell
proliferation on days 3 and 5 but was more significant
with the highest concentration tested, at 100 μM (#P <
0.05, *P < 0.01).
Figure 1 Effect of TA and DF on proliferation of MSC. MSCs were
treated with TA (A) and DF (B) for 5 days. Proliferation was measured
on days 0, 1, 3, and 5 using proliferation kit WST-1. Each data point
represents the mean ± SD of the three samples (*P < 0.01, #P < 0.05).
Figure 2 Effect of GDF-7 on differentiation of MSC to
tenocytes. Cells were grown in the medium with or without
GDF-7 (50 ng/ml). Gene expression of tenocyte markers TNMD (A)
and CollIα1 (B) was analyzed on days 0, 3, 6, and 9 using qPCR.
Each data point represents the mean ± SD of the three samples
(*P < 0.01, #P < 0.05).
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The peptide hormone GDF-7 was used to differentiate
MSC towards the tenocytic lineage. In Figure 2A,B, it
can be seen that GDF-7 increased the expression of the
tenocyte markers, tenomodulin (TNMD) and collagen
Iα1 (CollIα1) with more apparent effects at early time
points (#P < 0.05, *P < 0.01).Effect on tenocytic differentiation of MSC after exposure
to TA and DF
In preliminary experiments, we found that simultaneous
exposure of MSC to GDF-7 and DF or TA significantly
increased the appearance of adipocytes in culture dishes.
With DF, this was only seen after exposure to the highest
concentration tested, at 100 μM (data not shown). Regard-
ing TA, the appearance of adipocytes was seen with all
concentrations tested but was most clearly seen with the
highest concentration, at 100 nM (compare Figure 3A,B).
However, using the more sensitive qPCR technique, it is
clearly seen that TA, even at the lowest concentration and
at all time points, had a dramatic effect on aP2 gene
expression (Figure 4; #P < 0.05, *P < 0.01).Discussion
NSAIDs and periodic local corticosteroid injections still
represent the mainstays for the treatment of tendon-
related syndromes, although the majority of these con-
ditions are primarily degenerative rather than inflam-
matory [19]. Our results showed that, when exposed to
triamcinolone acetonide and diclofenac, the differenti-
ation of mesenchymal stem cells to tenocytic lineage
was impaired and the differentiation was drawn towards
adipocytic lineage.
We used GDF-7 (also named bone morphogenetic
protein (BMP)-12) to induce tenocytic differentiation of
the fibroblast-like C3H10T1/2 cells. BMPs belong to the
transforming growth factor beta superfamily, which is a
group of growth factors known to induce growth and
differentiation of various cell types [20]. Unlike the
major BMP family subtypes, such as BMP-2, BMP-4,
BMP-6, and BMP-7, which are essential for bone and
cartilage development [21], BMP-12 belongs to a sub-
type that lacks the propensity to induce bone formation.
Instead, molecules of this class, including BMP-12,
BMP-13, and GDF-5, were found to induce the forma-
tion of tendon-like structures [22]. Consistent with
Figure 3 Photomicrograph of untreated and 100 nM TA-treated MSC after 9 days of culture. Magnification × 10.
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two tendon-related markers, TNMD and CollIα1, signifi-
cantly increased with exposure to GDF-7. However, the
differentiated cells presented heterogeneous morpho-
logical features, and lipid droplets could be clearly seen in
part of the cell population. This was further confirmed on
the analysis of the expression of the adipocyte marker
gene, aP2, which codes for fatty acid binding protein [23].
We consider this finding of particular importance because
fatty infiltration in a musculotendinous junction character-
izes the histopathological changes following tendon injur-
ies, such as in massive rotator cuff tears (RCTs) [24].
Therefore, our results support the current opinion that
tendon stem cells may provide a rich source of adipocytes
in fatty degeneration [25]. We consider that adding GDF-
7 in C3H10T1/2 cultures might create a concise in vitro
model to study the biological process of this complex
orthopedic phenomenon.
Injectable corticosteroids have traditionally been used to
manage a variety of musculoskeletal disorders, although
the biological basis and systematic evidence for their bene-
fits are largely lacking. Their side effects are also well doc-
umented, such as infection, tendon ruptures, and skin and
subcutaneous fat atrophy [9]. In addition, experimental
studies suggest that corticosteroids not only damage theFigure 4 aP2 gene expression analysis after exposure to TA.
Cells were treated with GDF-7 (50 ng/ml) combined with or without
1, 10, or 100 nM TA. aP2 gene expression was measured on days 0,
3, 6, and 9 using qPCR. Each data point represents the mean ± SD of
the three samples (*P < 0.01, #P < 0.05).ultrastructure of collagen molecules [26] but also inhibit
the regenerative properties of tendon stem cells [27]. Sur-
prisingly, this evidence has not prevented the prevalence
of injectable corticosteroids in routine management of
tendon disorders. For example, a recent survey indicates
that 96% of practitioners believe that subacromial cortico-
steroid injection is efficacious in managing rotator cuff
tendinopathy [28]. We studied here the effects of TA, a
potent long-acting synthetic corticosteroid, on the
GDF-7-C3H10T1/2 cell model. We found that, besides
the known inhibitory effects on cell proliferation and
tenocytic differentiation, TA dramatically promoted
adipogenesis. This side effect deserves attention because
fatty degeneration is regarded as the key factor to compli-
cate surgical repair of RCTs (with failure rates reported as
high as 94% of patients) [29], and no effective treatment is
currently available to reverse its progression [24]. Our re-
sults therefore raise the question: should a medication that
makes the tendon injury irreparable be used for symptom
management in tendinopathies? To find the answer, fur-
ther research using in vitro and animal models are needed.
NSAIDs are widely prescribed to reduce pain and
inflammation following soft tissue injuries. They inhibit
tissue inflammation by repressing cyclooxygenase activity,
thereby leading to a reduction in pro-inflammatory prosta-
glandin synthesis. Despite the possible gastrointestinal and
cardiovascular side effects, some NSAIDs are sold as over-
the-counter medications and commonly taken by athletes
for traumatic or overload injuries [30]. DF is one of these
commonly used NSAIDs. It has a fast analgesic onset
and a long duration of action. Compared with the other
nonspecific NSAIDs, DF is well tolerated and rarely shows
serious side effects [31]. In the present study, we found
that the highest concentration (100 μM) of DF signifi-
cantly impaired cell growth and induced adipogenesis, but
such effects could not be seen at lower concentrations
(0.1–10 μM). This finding is consistent with the previous
in vitro study of Riley et al. which showed that 2 μg/ml
(6.7 μM) of DF had no negative influence on tendon cell
proliferation and glycosaminoglycan synthesis [32]. How-
ever, due to the limited number of tendon samples, only a
Fredriksson et al. Journal of Orthopaedic Surgery and Research 2013, 8:30 Page 5 of 6
http://www.josr-online.com/content/8/1/30single concentration of each drug was tested in their study.
Since the serum and soft tissue concentrations of DF after
oral intake or topical application are reported to be sel-
dom higher than 10 μM [33,34], further studies are needed
to identify whether tendon detrimental effects could really
happen following oral or topical application of DF. Up to
know, the only in vivo study comes from Marsolais et al.
who found that the mechanical properties of injured
rat Achilles tendons were identical in placebo and
diclofenac-treated groups [35]. However, intramuscular
DF injection is also popular for the management of
postoperative pain [36], and local DF injection has been
reported to manage hand tenosynovitis [37]. In both
conditions, the para- or intratendinous DF concentra-
tion might be higher than 100 μM. Therefore, side
effects on tendons should be taken into account when
evaluating the safety of these procedures.
Taken together, we established an in vitro model to study
tenocyte differentiation from their multipotent progenitors.
Our results showed that pharmaceuticals such as DF and
TA which are commonly used in the symptomatic treat-
ment of musculoskeletal disorders may have profound
negative effects on tendon regeneration on a progenitor
cell level and therefore should be used with caution.
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